The DOI matches its Crossref record; 96 of the 98 references it cites were found in a registry or an index.
Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)
Open accessAbstract
The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May 2012. About 100 basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included "Indications overlapping with epilepsy" and "Securing the successful development of an investigational antiepileptic drug in the current environment". Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the EILAT X report, the current manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel and other AMPA receptor antagonists, tonabersat, valnoctamide and its homologue sec-propylbutylacetamide (SPD), VX-765 and YK3089. Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although, there is an abundance of diverse antiepileptic drugs, most of them exert their actions by inhibition of the voltage-gated sodium or calcium channels or by potentiation of the GABA-mediated synaptic transmission [11], which results in a symptomatic approach in most cases; the goal of these drugs is to eliminate or at least reduce the number and/or severity of seizures.”
From Hippocampal neuro-networks and dendritic spine perturbations in epileptogenesis are attenuated by neuroprotectin D1 (2015) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1430 · Cited by 1,243
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & White, H. S. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 614
Self-citationMehta, A. K., & Ticku, M. K. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00052-6 · Cited by 613
The role of cytokines in the pathophysiology of epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.03.009 · Cited by 564
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 544
Self-citation(2004) · Wiley eBooks · doi:10.1002/9780470752463 · Cited by 509
Adjunctive perampanel for refractory partial-onset seizures
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 478
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Self-citation
Research works printed but not linked: 13
- Biton, 2009, Brivaracetam as adjunctive treatment of refractory partial-onset seizures in adults: results from two randomized, double-blind, placebo-controlled trials, Epilepsia, 50, 106
- Brodsky, 2007, Safety and tolerability of brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures, Epilepsia, 48, 342
- Kwan, 2009, Safety and tolerability of brivaracetam as adjunctive treatment in adults with refractory epilepsy: randomized, double-blind, placebo-controlled trial, Epilepsia, 50, 107
- Niespodziany, 2009, Brivaracetam modulates Na+ currents expressed in a neuroblastoma cell line compared with carbamazepine, Epilepsia, 50, 107
- Rostock, 1998, AWD 131-138 is a potential novel anxiolytic without sedation and amnesia: a comparison with diazepam and buspirone, Naunyn-Schmied. Arch. Pharmacol., 358, R68
- Sargentini-Maier, 2008, Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects, Epilepsia, 49, 452
- Stafstrom, 2007, 2-Deoxyglucose effects on spatial learning and exploratory behavior in rodents, Epilepsia, 48, 299
- Stockis, 2009, Interaction study between brivaracetam and a combination oral contraceptive, Epilepsia, 50, 96
- Sutula, 2008, Dose-response and time course of action of disease-modifying effects of 2DG on kindling progression: effectiveness of administration after seizures, Epilepsia, 49, 382
- Tober, 1998, AWD 131-138: a derivative of a series of imidazolinones with anticonvulsant activity, Naunyn-Schmied. Arch. Pharmacol., 358, R68
- Tober, 1999, Anticonvulsant activity of AWD 131-138 in genetic animal models of epilepsy, Naunyn-Schmied. Arch. Pharmacol., 359, R97
- Van Paesschen, 2007, Efficacy and tolerability of 50 and 150mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial onset epilepsy, Epilepsia, 48, 329
- Wasterlain, 2009, Short-term and long-term effects of brivaracetam in an animal model of status epilepticus, Epilepsia, 50, 13
Cited by
Sorted by citations
Items 201–244 of 244
Löscher, W., White, H. S., & Klein, P. (2026) · CNS Drugs · doi:10.1007/s40263-026-01284-x · Cited by 3
Self-citationThe Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy
Choi, Y. M., White, H. S., Klein, P., & Löscher, W. (2026) · CNS Drugs · doi:10.1007/s40263-026-01290-z · Cited by 2
Self-citationCenobamate: A comprehensive review
Vossler, D. G., & Sankar, R. (2026) · Seizure · doi:10.1016/j.seizure.2026.04.011 · Cited by 2
Conceptual and molecular docking study of newly developed antiepileptic drug cenobamate
Ilyas, A., Nazar, S., Siddiqui, N., Alam, O., Shaharyar, M., & Siddiqui, S. (2023) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2023.17.3.0373 · Cited by 2
Epilepsy in patients with glioblastoma: Mechanisms of occurrence and problems of treatment (part 2)
Vasilenko, А. V., Ulitin, А. Y., Lebedev, I. A., Ablaev, N. R., Викторович, Д. М., Mansurov, A. S., & Shaikhov, M. M. (2024) · Medical alphabet · doi:10.33667/2078-5631-2023-33-13-19 · Cited by 2
Cohen, M. V., & Downey, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105477 · Cited by 2
Recent Advances and Future Directions in the Treatment of Epilepsy
Kurokawa, T., Kazuta, Y., & Watanabe, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12436-9 · Cited by 2
Wang, Z., Ke, C.-L., & Liu, J. (2023) · Reaction Chemistry & Engineering · doi:10.1039/d2re00524g · Cited by 2
New Findings on the Crystal Polymorphism of Imepitoin
Bruni, G., Capsoni, D., Pellegrini, A., Altomare, A., Coduri, M., Ferrara, C., Galinetto, P., & Molteni, R. (2024) · Molecules · doi:10.3390/molecules29081724 · Cited by 1
Pyroptosis in epilepsy: from pathophysiological mechanisms to therapeutic strategies
Chen, Q., Yang, Y.-T., Cai, L., Zhang, H., & Yang, J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1793636 · Cited by 1
Abdullahi, A. M., Abdulrazak, U. I., & Abdullahi, I. M. (2026) · Neuroglia · doi:10.3390/neuroglia7020014 · Cited by 1
The cumulative impact of seizures: the science underlying how seizures beget seizures
Gustin, R. M., Gholipour, T., & Peters, J. M. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1793970 · Cited by 1
Swamikannu, B., Kumar, K. S., Jayesh, R., Rajendran, S., Muthupalani, R. S., & Ramanathan, A. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.5.2743 · Cited by 1
Galtrey, C. M., & Cock, H. R. (2015) · Neuropsychiatric symptoms of neurological disease · doi:10.1007/978-3-319-22159-5_15 · Cited by 1
Novel Molecular Targets for Drug-Treatment of Epilepsy
Belcastro, V., & Verrotti, A. (2014) · Contemporary clinical neuroscience · doi:10.1007/978-3-319-12283-0_10 · Cited by 1
Use of Animal Models for Epilepsy Research and Therapy Development
Barker‐Haliski, M. L., & White, H. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00007-9 · Cited by 1
Self-citationBroekaart, D. W. M., Korotkov, A., Gorter, J. A., & van Vliet, E. A. (2021) · Progress in inflammation research · doi:10.1007/978-3-030-67403-8_4 · Cited by 1
Médicaments antiépileptiques : quoi de neuf récemment ?
Guery, D., & Rheims, S. (2022) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2022.07.006 · Cited by 2
Sanders, S. G. (2015) · doi:10.1002/9781118689691.ch7 · Cited by 1
Epilepsy and Related Seizure Disorders
Tracz, J. A., & Musto, A. E. (2025) · doi:10.1002/9783527844678.ch4 · Cited by 1
Neue Arzneimittel für Kleintiere 2013
Emmerich, I. U. (2014) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/s-0038-1623771
Delanty, N., & White, H. S. (2015) · doi:10.1002/9781118936979.ch55
Self-citationEpilepsy in glioblastoma patients: basic mechanisms and current problems in
Bruna, J., & Juliá (2013)
Silva, R. F. R. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Antiepileptic drugs: newer targets and new drugs
Chawan, V. S., Phatak, A. M., Gawand, K. V., Badwane, S. V., & Panchal, S. (2016) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20161495
Gandrathi, A. (2016) · Minerva Access (University of Melbourne)
Investigational Treatments for Status Epileptics
Haque, A., VanHaerents, S. A., & Drislane, F. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-31230-9_31
Ictogenic and Epileptogenic Mechanisms of Neuroinflammation: Insights From Animal Models
Balosso, S., Ravizza, T., & Vezzani, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-53088-0.00004-x · Cited by 1
Wei, Q., Feng, J., He, C., & Hua, Z. (2018) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2018.05.10
Epilepsy Mutations in Different Regions of the Nav1.2 Channel Cause Distinct Biophysical Effects
Mason, E. R. (2020) · IUScholarWorks (Indiana University) · doi:10.7912/c2/341
Pietrzak, Z., Stefaniak, M., Dzikowski, P., Nowicka, E., Obel, M., & Piecewicz‐Szczęsna, H. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.02.005
Febrile status epilepticus-related epilepsy: Neuroinflammation and epigenetics
Ravizza, T., Vezzani, A., & Baram, T. Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89932-1.00018-4
Masson, S., Bleuer‐Elsner, S., Muller, G., Médam, T., Chevallier, J., & Gaultier, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-53012-8_23
Majkowska-Zwolińska, B. (2023) · Journal of Epileptology · doi:10.2478/joepi-2023-0002
Zennati, A., & Khabbal, Y. (2024) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v8i12.2
Peripheral Neuropathy Induced by Topiramate
Kissa, N., & Bencharfa, Z. (2025) · Scholars Journal of Medical Case Reports · doi:10.36347/sjmcr.2025.v13i07.044
Sean Sanders DVM, P. (2025) · Wiley eBooks · doi:10.1002/9781394245642.ch7
Targeting voltage-gated potassium channels for the treatment of genetic epilepsy
He, G., & Liu, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00060-1
Synergistic targeting of MCL1 and caspases for enhanced anti-tumor immunity in breast cancerPreprint
Yi, J. K., Lee, J., Kim, P., Shaw, L. M., & Spektor, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.10.681458
Bleuer‐Elsner, S., Masson, S., Lacoste, M., & Muller, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-06260-4_22
Qu, X., Chen, L., He, J., Fang, Y., Sun, J., Yu, Z., Yang, Z., Zhang, Z. S., Chen, J., & 董玲 (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157907
Wang, Y., Zheng, W., Jiang, F., Sun, Y., & Zheng, D. (2026) · Epilepsy Research · doi:10.1016/j.eplepsyres.2026.107850
BindingDB (2020) · UC San Diego · doi:10.7270/q27h1nkt
Metadata
- Authors
- Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Oslo University Hospital (NO)
- University of Washington (US)
- University of Pavia (IT)
- Karolinska Institutet (SE)
- University of Utah (US)
- Corresponding author
- Bialer, Meir
- Venue
- Epilepsy Research
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 103
- Issue
- 1
- Pages
- 2-30
- ISSN
- 0920-1211 (ISSN-L)
- OpenAlex
- W2203865877
- Cited by
- 243
- References
- 98
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 20 · 2021: 17 · 2020: 32 · 2019: 12 · 2018: 10 · 2017: 19 · 2016: 17 · 2015: 23 · 2014: 24 · 2013: 20
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Epilepsy Research (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- UCB Pharma
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- antiepileptic drugs, drug development, preclinical pharmacology, clinical pharmacology, brivaracetam, 2-deoxyglucose, ganaxolone, perampanel, AMPA receptor antagonists, tonabersat, retigabine, ezogabine, VX-765, epilepsy
- MeSH terms
- Animals, Anticonvulsants, Clinical Trials as Topic, Congresses as Topic, Epilepsy, Humans, Israel, Drugs, Investigational, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
